First-line single-agent panitumumab in frail elderly patients with wild-type KRAS metastatic colorectal cancer and poor prognostic factors: A phase II study of the Spanish Cooperative Group for the Treatment of Digestive Tumours
European Journal of Cancer2015Vol. 51(11), pp. 1371–1380
Citations Over TimeTop 10% of 2015 papers
Javier Sastre, Bartomeu Massutí, G. Pulido, Carmen Guillén‐Ponce, Manuel Benavides, José Luís Zamora Manzano, Margarita Reboredo, Fernando Rivera, Cristina Grávalos, María José Safont, M. Martínez Villacampa, Patricia Llovet, E. Dotor, Eduardo Díaz‐Rubio, Enrique Aranda
Related Papers
- → Targeting colorectal cancer with human anti-EGFR monoclonocal antibodies: focus on panitumumab(2008)47 cited
- → Treatment with Panitumumab After a Severe Infusion Reaction to Cetuximab in a Patient with Metastatic Colorectal Cancer: A Case Report(2007)45 cited
- → The effectiveness of cetuximab and panitumumab when combined with FOLFIRI in second-line treatment of KRAS wild type metastatic colorectal cancers. Single centre experience(2020)2 cited
- → The Cost Study of Cetuximab and Panitumumab in The First-Line Treatment of Mcrc in The Czech Republic(2017)
- ASPECCT: panitumumab versus cetuximab for colorectal cancer(2014)